• PYR-41: Selective Inhibitor of Ubiquitin-Activating Enzym...

  2026-02-23

  PYR-41 is a selective inhibitor of Ubiquitin-Activating Enzyme (E1) used to dissect the ubiquitin-proteasome system in cellular and in vivo models. This compound enables precise modulation of protein degradation and NF-κB signaling, making it indispensable for research into apoptosis, inflammation, and cancer therapeutics. Its well-characterized solubility, dosage parameters, and preclinical efficacy support its widespread use in molecular biology laboratories.

• SB203580: Selective p38 MAPK Inhibitor for Pathway Dissec...

  2026-02-23

  SB203580 empowers researchers to precisely interrogate the p38 MAPK signaling pathway, revealing new strategies for targeting inflammation, neuroprotection, and multidrug resistance. Its potent, ATP-competitive inhibition and dual-action mechanisms make it an indispensable tool for overcoming experimental bottlenecks in cancer and stress biology.

• LY2228820: Selective ATP-Competitive p38 MAP Kinase Inhib...

  2026-02-22

  LY2228820 is a potent, selective ATP-competitive inhibitor targeting p38α and p38β MAPK, offering robust inhibition of p38 MAPK signaling for anti-inflammatory and cancer research. Its dual-action mechanism both blocks kinase activity and accelerates dephosphorylation, enabling precise modulation of cellular stress responses. APExBIO’s A5566 kit delivers reproducible results in diverse experimental workflows.

• LY2228820: Selective p38 MAP Kinase Inhibitor for Cancer ...

  2026-02-21

  LY2228820 redefines experimental precision as a selective p38 MAP kinase inhibitor, combining ATP-competitive potency with dual-action dephosphorylation. Its nanomolar efficacy and robust workflow compatibility drive reproducible results in anti-inflammatory, apoptosis, and angiogenesis research. Explore how this tool from APExBIO accelerates bench-to-translational breakthroughs and streamlines troubleshooting.

• 12-O-tetradecanoyl Phorbol-13-acetate: Unraveling ERK/MAP...

  2026-02-20

  Explore how 12-O-tetradecanoyl phorbol-13-acetate (TPA) drives advanced ERK/MAPK pathway activation and tumor promotion in modern signal transduction research. This in-depth analysis reveals unique mechanistic insights and translational implications for skin cancer models, distinguishing this article from standard protocol guides.

• Optimizing Signal Transduction: 12-O-tetradecanoyl phorbo...

  2026-02-20

  This article addresses key experimental challenges in ERK/MAPK pathway studies, highlighting how 12-O-tetradecanoyl phorbol-13-acetate (TPA), SKU N2060, delivers reproducible, sensitive activation across cell viability, proliferation, and carcinogenesis models. Drawing on quantitative data, practical protocol guidance, and peer-reviewed findings, it provides actionable insights for biomedical researchers and laboratory technicians.

• Toremifene (SKU A3884): Evidence-Based Solutions for Repr...

  2026-02-19

  This in-depth article addresses real lab challenges in hormone-responsive and metastatic prostate cancer research, demonstrating how Toremifene (SKU A3884) empowers scientists with reproducible, quantitative, and workflow-optimized solutions. Scenario-driven Q&A blocks provide practical guidance on experimental design, data interpretation, and vendor selection, highlighting the compound’s rigorously characterized IC50 and compatibility for in vitro assays.

• PYR-41: Selective Ubiquitin-Activating Enzyme Inhibitor f...

  2026-02-19

  PYR-41, a potent inhibitor of Ubiquitin-Activating Enzyme E1, empowers researchers to dissect protein degradation pathways, modulate NF-κB signaling, and model immune evasion in viral and oncologic contexts. Its unique workflow adaptability and robust inhibition profile make PYR-41 from APExBIO a strategic asset for advanced ubiquitination research and translational applications.

• SB203580: Selective p38 MAPK Inhibitor for Mechanistic Pa...

  2026-02-18

  SB203580 is a highly selective, ATP-competitive p38 MAP kinase inhibitor used to dissect p38 MAPK signaling pathway mechanisms. Its established potency and specificity make it a gold standard in kinase signaling and inflammatory disease research. This article details SB203580’s mode of action, benchmarks, and practical considerations for advanced experimental workflows.

• SB203580: Selective p38 MAPK Inhibitor for Disease Modeling

  2026-02-18

  SB203580, a potent and selective p38 MAP kinase inhibitor, empowers researchers to unravel stress, inflammation, and resistance mechanisms with extraordinary precision. Its unique ATP-competitive action and compatibility with diverse experimental models position it as a gold-standard tool for translational studies in cancer biology, neuroprotection, and inflammatory disease.

• SD 169: Selective ATP Competitive Inhibitor for p38 MAPK ...

  2026-02-17

  SD 169 (indole-5-carboxamide) sets a new benchmark for selective p38α and p38β MAP kinase inhibition, delivering robust, reproducible modulation of inflammatory and neuroregenerative pathways. Its dual-action mechanism and workflow-centric reliability distinguish it as a must-have tool for advanced cell signaling, apoptosis, and disease modeling studies.

• SB 202190: Selective p38 MAPK Inhibitor Empowering Inflam...

  2026-02-17

  SB 202190 stands out as a highly selective p38 MAP kinase inhibitor, offering researchers unparalleled specificity for dissecting MAPK signaling in inflammation, apoptosis, and cancer models. Leveraging its potent, ATP-competitive inhibition, this compound streamlines experimental workflows and unlocks new dimensions in translational research.

• Bufalin: Advanced Workflows for Triple-Negative Breast Ca...

  2026-02-16

  Bufalin, a cardiotonic steroid and molecular glue degrader of estrogen receptor alpha, is redefining experimental strategies in triple-negative breast cancer and hepatocellular carcinoma research. This article details robust, scenario-driven workflows and troubleshooting guidance, highlighting APExBIO’s validated Bufalin for reliable, data-driven oncology discovery.

• VX-765: Selective Caspase-1 Inhibitor for Advanced Inflam...

  2026-02-16

  VX-765, a potent and selective oral caspase-1 inhibitor, empowers researchers to dissect inflammasome-driven pathways, modulate pyroptosis, and selectively inhibit IL-1β and IL-18 release. Its workflow versatility, high selectivity, and proven efficacy in preclinical disease models set it apart as a tool of choice for inflammation and cell death studies.

• VX-765: Selective Caspase-1 Inhibitor for Advanced Inflam...

  2026-02-15

  VX-765 stands out as a potent, orally active caspase-1 inhibitor, enabling precise modulation of IL-1β and IL-18 in models ranging from atherosclerosis to HIV-induced pyroptosis. Its high selectivity and robust preclinical validation make it indispensable for dissecting inflammasome-driven pathways and optimizing translational inflammation studies.

8612 records 23/575 page Previous Next First page 上5页 2122232425 下5页 Last page